AI assistant
Protara Therapeutics, Inc. — Director's Dealing 2023
Jan 20, 2023
34057_dirs_2023-01-20_f5bbaa2b-a180-4042-8abc-659a01420071.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Protara Therapeutics, Inc. (TARA)
CIK: 0001359931
Period of Report: 2023-01-19
Reporting Person: Shefferman Jesse (Director, CEO and President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-01-19 | Common Stock | A | 51300 | $0.00 | Acquired | 918282 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-01-19 | Stock Option (Right to Buy) | $3.02 | A | 307500 | Acquired | 2033-01-18 | Common Stock (307500) | Direct |
Footnotes
F1: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 19, 2023.
F2: 25% of the shares vest on the one year anniversary of January 19, 2023 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.